Filed with the SEC on · Summarized by InvestorsBot
Pablo J. Cagnoni, Incyte Corp.’s President and Global Head of R&D, sold 15,888 shares of common stock on July 31 at $119.70 per share, for approximately $1.90 million. He owned 215,444 shares after the transaction.
Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.
Subscribe freeIncyte EVP Patrick Mayes sells $5.7M in stock
Form 4 · Insider Trade · August 4, 2026
Incyte reports Q2 revenue growth and raises 2026 sales guidance
8-K · July 28, 2026
Incyte ($INCY) filed an 8‑K (Item 9.01) furnishing a press release dated Mar 25, 2026 (Exhibit 99.1) and…
8-K · March 26, 2026
Effective Mar 25, 2026, Incyte announced exec title changes: Pablo J.
8-K · March 26, 2026
FDA issued a Complete Response Letter on Feb 27, 2026 for the sBLA for Zynyz® (retifanlimab‑dlwr) 375mg…
8-K · March 6, 2026
Incyte files Form 8‑K (Item 9.01) dated Feb 10, 2026 to furnish a press release (Exhibit 99.1); Cover Page…
8-K · February 10, 2026